Nearly a quarter of a million Americans each year may be hospitalized with bleeding complications caused by needlessly taking a daily dose of an adult-sized aspirin rather than a baby aspirin to prevent a heart attack or stroke.
A combination of three different drugs that block the HER-2 receptor, a critical cellular growth signal for some breast cancers, eradicated aggressive breast tumors in mice and could point the way toward developing better treatments in patients, said researchers from the Breast Center at Baylor College of Medicine in a report that appears in the Journal of the National Cancer Institute.
Baylor College of Medicine surgeons in the trauma center at Ben Taub General Hospital hope to determine if lowering blood pressure in patients undergoing operations to repair serious injuries to the chest and abdomen can reduce their risk of dying.
The efforts of the Baylor International Pediatric AIDS Initiative expanded in a new direction with the opening of a state-of-the-art laboratory in partnership with and located at the Stefan S. Nicolau Institute of Virology in Bucharest, Romania.
A growing shortage of allergists in the United States may soon impact the quality of patient care for asthma and other allergic diseases, according to a report published by the American College of Allergy, Asthma and Immunology (ACAAI).
Dementia may be avoidable and doctors should take a more optimistic approach to the condition, according to research involving two UNSW academics.
Researchers from four organizations have identified more than 200 new proteins that bind to normal and mutant forms of the protein that causes Huntington’s disease (HD).
No one is at zero risk for stroke, which explains why it is vital to know the signs and understand how to decrease the chance of experiencing a stroke.
Boehringer Ingelheim GmbH announced that it has initiated and begun enrollment of patients in the ArTEN trial, which will compare the efficacy and safety of Viramune? (nevirapine), a non-nucleoside reverse transcriptase inhibitor (NNRTI), dosed once daily (QD) or twice daily (BID), versus atazanavir/ritonavir, a once-daily dosed protease inhibitor (PI).
The New England Journal of Medicine is publishing results from two Phase III studies of Merck’s cervical cancer vaccine, GARDASIL [Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine].